Rapport Therapeutics, Inc.
RAPPHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Rapport Therapeutics, Inc. (RAPP) is listed under Biotechnology. At a $2.04B market cap, Rapport Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Market Cap
$2.04B
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
-9.69
EPS (TTM)
$-2.76
EPS (Fwd)
$-4.40
ROE
-28.3%
ROA
-19.1%
Cash
$476.8M
Total Debt
$10.8M
Free CF
-$49.4M
52W Change
190.3%
Annual Financials
Cash vs Debt
With $476.8M in cash and $10.8M in debt, RAPP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$49.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -28.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, RAPP has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RAPP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.